• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2019冠状病毒病大流行时代的尼古丁治疗与戒烟：一个有趣的联盟。

Nicotine treatment and smoking cessation in the era of COVID-19 pandemic: an interesting alliance.

作者信息

Boutou Afroditi K, Pitsiou Georgia, Kontakiotis Theodore, Kioumis Ioannis

机构信息

Dept of Respiratory Medicine, G. Papanikolaou Hospital, Thessaloniki, Greece.

Dept of Respiratory Failure, Aristotle University of Thessaloniki, Thessaloniki, Greece.

出版信息

ERJ Open Res. 2020 Aug 11;6(3). doi: 10.1183/23120541.00306-2020. eCollection 2020 Jul.

DOI:10.1183/23120541.00306-2020
PMID:32802824
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7418819/
Abstract

https://bit.ly/3fpsBdq.

摘要

https://bit.ly/3fpsBdq. （此为网址，直接保留英文形式符合要求，若强行翻译为中文可能导致无法正常使用该网址，所以这里不进行翻译）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00ba/7418819/cd194ec97783/00306-2020.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00ba/7418819/cd194ec97783/00306-2020.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00ba/7418819/cd194ec97783/00306-2020.01.jpg

相似文献

1
Nicotine treatment and smoking cessation in the era of COVID-19 pandemic: an interesting alliance.2019冠状病毒病大流行时代的尼古丁治疗与戒烟：一个有趣的联盟。
ERJ Open Res. 2020 Aug 11;6(3). doi: 10.1183/23120541.00306-2020. eCollection 2020 Jul.
2
Nicotine receptor partial agonists for smoking cessation.用于戒烟的尼古丁受体部分激动剂。
Cochrane Database Syst Rev. 2012 Apr 18(4):CD006103. doi: 10.1002/14651858.CD006103.pub6.
3
Nicotine receptor partial agonists for smoking cessation.用于戒烟的尼古丁受体部分激动剂。
Cochrane Database Syst Rev. 2011 Feb 16(2):CD006103. doi: 10.1002/14651858.CD006103.pub5.
4
Nicotine receptor partial agonists for smoking cessation.用于戒烟的尼古丁受体部分激动剂。
Cochrane Database Syst Rev. 2010 Dec 8(12):CD006103. doi: 10.1002/14651858.CD006103.pub4.
5
Nicotine receptor partial agonists for smoking cessation.用于戒烟的尼古丁受体部分激动剂。
Cochrane Database Syst Rev. 2008 Jul 16(3):CD006103. doi: 10.1002/14651858.CD006103.pub3.
6
Smoking Cessation as a Public Health Measure to Limit the Coronavirus Disease 2019 Pandemic.将戒烟作为一项公共卫生措施以限制2019年冠状病毒病大流行。
Eur Cardiol. 2020 Apr 23;15:e16. doi: 10.15420/ecr.2020.11. eCollection 2020 Feb.
7
Telehealth: "virtual" lifeline for home-ventilated patients during the COVID-19 pandemic.远程医疗：新冠疫情期间居家通气患者的“虚拟”生命线。
ERJ Open Res. 2020 Sep 28;6(3). doi: 10.1183/23120541.00399-2020. eCollection 2020 Jul.
8
Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era.全球医疗服务提供者对COVID-19时代间质性肺疾病患者电子健康的经验与看法。
ERJ Open Res. 2021 Aug 31;7(3). doi: 10.1183/23120541.00405-2021. eCollection 2021 Jul.
9
Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up.减少吸烟量可促进戒烟：一项为期2年随访的尼古丁口香糖双盲、随机、安慰剂对照试验的结果。
Addiction. 2003 Oct;98(10):1395-402. doi: 10.1046/j.1360-0443.2003.00489.x.
10
Efficacy and safety of nicotine replacement therapy for smoking cessation in pregnancy: systematic review and meta-analysis.尼古丁替代疗法在妊娠期戒烟中的疗效和安全性：系统评价和荟萃分析。
Addiction. 2011 Jan;106(1):52-61. doi: 10.1111/j.1360-0443.2010.03179.x. Epub 2010 Nov 4.

引用本文的文献

1
Google Trends Assessment of Keywords Related to Smoking and Smoking Cessation During the COVID-19 Pandemic in 4 European Countries: Retrospective Analysis.4个欧洲国家在2019年冠状病毒病大流行期间与吸烟和戒烟相关关键词的谷歌趋势评估：回顾性分析
Online J Public Health Inform. 2024 Dec 3;16:e57718. doi: 10.2196/57718.
2
Analysis of influencing factors on long COVID in COVID-19 patients infected with omicron variant three months after discharge: a cross-sectional study.奥密克戎变异株感染 COVID-19 患者出院后 3 个月长新冠影响因素分析：一项横断面研究。
BMC Infect Dis. 2024 Jan 2;24(1):36. doi: 10.1186/s12879-023-08947-w.
3

本文引用的文献

1
Epidemiological and Clinical Characteristics of Cases During the Early Phase of COVID-19 Pandemic: A Systematic Review and Meta-Analysis.COVID-19大流行早期病例的流行病学和临床特征：系统评价与荟萃分析
Front Med (Lausanne). 2020 Jun 11;7:295. doi: 10.3389/fmed.2020.00295. eCollection 2020.
2
Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.预测感染意大利公民中严重或致命的 COVID-19 的因素，包括血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂。
PLoS One. 2020 Jun 24;15(6):e0235248. doi: 10.1371/journal.pone.0235248. eCollection 2020.
3
Does Tobacco Use Enhance the Risk of SARS-CoV-2 Infection: Evidence from Eastern Indian Population.
吸烟会增加感染新型冠状病毒的风险吗：来自印度东部人群的证据。
Addict Health. 2023 Jul;15(3):163-168. doi: 10.34172/ahj.2023.1400. Epub 2023 Jul 29.
4
Electronic cigarette use and risk of COVID-19 among young adults without a history of cigarette smoking.电子香烟使用与无吸烟史的年轻人感染 COVID-19 的风险。
Prev Med. 2022 Sep;162:107151. doi: 10.1016/j.ypmed.2022.107151. Epub 2022 Jul 6.
5
Tobacco Smoking and Risk of SARS-CoV-2 Infection and Disease Severity Among Adults in an Integrated Healthcare System in California.加州综合医疗体系中成年人吸烟与感染 SARS-CoV-2 及疾病严重程度的关系。
Nicotine Tob Res. 2023 Jan 5;25(2):211-220. doi: 10.1093/ntr/ntac090.
6
Changes in the respiratory function of COVID-19 survivors during follow-up: A novel respiratory disorder on the rise?COVID-19 幸存者随访期间呼吸功能的变化：新兴的新型呼吸疾病？
Int J Clin Pract. 2021 Oct;75(10):e14301. doi: 10.1111/ijcp.14301. Epub 2021 May 17.
7
Smoking and COVID-19: A Scoping Review.吸烟与2019冠状病毒病：一项范围综述
Tob Use Insights. 2021 Feb 15;14:1179173X21994612. doi: 10.1177/1179173X21994612. eCollection 2021.
8
Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case-control study from western Rajasthan, India.吸烟、饮酒及其他导致有症状新冠病毒病与无症状严重急性呼吸综合征冠状病毒2感染的风险因素：一项来自印度拉贾斯坦邦西部的病例对照研究
Trans R Soc Trop Med Hyg. 2021 Jul 1;115(7):820-831. doi: 10.1093/trstmh/traa172.
9
Current developments and future directions in COPD.COPD 的现状和未来发展方向。
Eur Respir Rev. 2020 Dec 2;29(158). doi: 10.1183/16000617.0289-2020. Print 2020 Dec 31.
Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.
神经调控疗法在 COVID-19 中控制炎症及相关器官功能障碍的意义。
J Cardiovasc Transl Res. 2020 Dec;13(6):894-899. doi: 10.1007/s12265-020-10031-6. Epub 2020 May 26.
4
Tobacco smoking and COVID-19 pandemic: old and new issues. A summary of the evidence from the scientific literature.吸烟与新冠疫情：新旧问题。科学文献证据总结。
Acta Biomed. 2020 May 11;91(2):106-112. doi: 10.23750/abm.v91i2.9698.
5
Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China.中国浙江省 465 例新冠肺炎（COVID-19）住院病例的流行病学、临床和病毒学特征。
Influenza Other Respir Viruses. 2020 Sep;14(5):564-574. doi: 10.1111/irv.12758. Epub 2020 May 19.
6
Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19.开发和验证一种临床风险评分，以预测 COVID-19 住院患者发生危重症的情况。
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089. doi: 10.1001/jamainternmed.2020.2033.
7
Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis.COPD 与 COVID-19 患者吸烟的流行率、严重程度和死亡率：一项快速系统评价和荟萃分析。
PLoS One. 2020 May 11;15(5):e0233147. doi: 10.1371/journal.pone.0233147. eCollection 2020.
8
Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19.超越戒烟：研究药用尼古丁预防和治疗新冠病毒疾病
Nicotine Tob Res. 2020 Aug 24;22(9):1669-1670. doi: 10.1093/ntr/ntaa077.
9
Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system.社论：尼古丁与严重急性呼吸综合征冠状病毒2：2019冠状病毒病可能是一种烟碱能胆碱能系统疾病。
Toxicol Rep. 2020 Apr 30;7:658-663. doi: 10.1016/j.toxrep.2020.04.012. eCollection 2020.
10
COVID-19 and smoking: is nicotine the hidden link?新型冠状病毒肺炎与吸烟：尼古丁是隐藏的关联吗？
Eur Respir J. 2020 Jun 4;55(6). doi: 10.1183/13993003.01116-2020. Print 2020 Jun.